Green Cross (XKRX:006280) FCF Margin % : 13.62% (As of Dec. 2023)

View and export this data going back to 1989. Start your Free Trial

What is Green Cross FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Green Cross's Free Cash Flow for the three months ended in Dec. 2023 was ₩55,148 Mil. Green Cross's Revenue for the three months ended in Dec. 2023 was ₩404,944 Mil. Therefore, Green Cross's FCF Margin % for the quarter that ended in Dec. 2023 was 13.62%.

As of today, Green Cross's current FCF Yield % is -10.15%.

The historical rank and industry rank for Green Cross's FCF Margin % or its related term are showing as below:

XKRX:006280' s FCF Margin % Range Over the Past 10 Years
Min: -8.63 Med: -4.07 Max: 1.43
Current: -8.08

During the past 13 years, the highest FCF Margin % of Green Cross was 1.43%. The lowest was -8.63%. And the median was -4.07%.

XKRX:006280's FCF Margin % is ranked worse than
65.69% of 1026 companies
in the Drug Manufacturers industry
Industry Median: -0.675 vs XKRX:006280: -8.08

Green Cross FCF Margin % Historical Data

The historical data trend for Green Cross's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Green Cross FCF Margin % Chart

Green Cross Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-7.91

-4.35

0.16

1.43

-8.08

Green Cross Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															14.28	-22.19	-7.94	-17.00	13.62

Competitive Comparison of Green Cross's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Green Cross's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Green Cross's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Green Cross's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Green Cross's FCF Margin % falls into.

Green Cross FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Green Cross's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-131464.311	/	1626643.816
	=	-8.08 %

Green Cross's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	55147.679	/	404944.309
	=	13.62 %

Green Cross FCF Margin % Related Terms

Thank you for viewing the detailed overview of Green Cross's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Green Cross (XKRX:006280) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Green Cross Corp (XKRX:006280) » Definitions » FCF Margin %

Traded in Other Exchanges

N/A

Address

303 Bojeong-Dong, Giheung-Gu, Yongin, Gyeonggi, KOR, 449-070

Website

http://www.greencross.com

Green Cross Corp is one of the global leaders in the healthcare sector. The Montreal-based biopharmaceutical company primarily develops intravenous immunoglobulin (IVIG), a key therapeutic solution for the treatment of patients with infectious and immune diseases, and albumin, used as a blood-volumizing agent and in the treatment of burns. Currently, the company has a global presence through its association with various subsidiaries.

Green Cross (XKRX:006280) Headlines

No Headlines